ATE401902T1 - Ganoderma lucidum sporen zur behandlung von systemischem lupus erytrhomatosus (sle) - Google Patents

Ganoderma lucidum sporen zur behandlung von systemischem lupus erytrhomatosus (sle)

Info

Publication number
ATE401902T1
ATE401902T1 AT03255547T AT03255547T ATE401902T1 AT E401902 T1 ATE401902 T1 AT E401902T1 AT 03255547 T AT03255547 T AT 03255547T AT 03255547 T AT03255547 T AT 03255547T AT E401902 T1 ATE401902 T1 AT E401902T1
Authority
AT
Austria
Prior art keywords
ganoderma lucidum
lucidum spores
test
systemic lupus
germinated
Prior art date
Application number
AT03255547T
Other languages
English (en)
Inventor
Chee-Keung Chung
Siu Kan Tong
Original Assignee
Chee-Keung Chung
Siu Kan Tong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chee-Keung Chung, Siu Kan Tong filed Critical Chee-Keung Chung
Application granted granted Critical
Publication of ATE401902T1 publication Critical patent/ATE401902T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
AT03255547T 2002-09-05 2003-09-05 Ganoderma lucidum sporen zur behandlung von systemischem lupus erytrhomatosus (sle) ATE401902T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/234,103 US6893641B2 (en) 1999-10-12 2002-09-05 Ganoderma lucidum spores for treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
ATE401902T1 true ATE401902T1 (de) 2008-08-15

Family

ID=31887686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03255547T ATE401902T1 (de) 2002-09-05 2003-09-05 Ganoderma lucidum sporen zur behandlung von systemischem lupus erytrhomatosus (sle)

Country Status (8)

Country Link
US (1) US6893641B2 (de)
EP (1) EP1398036B1 (de)
JP (1) JP2004099613A (de)
CN (1) CN1480207A (de)
AT (1) ATE401902T1 (de)
CA (1) CA2437690A1 (de)
DE (1) DE60322310D1 (de)
ES (1) ES2311086T3 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251672A1 (en) * 2005-05-03 2006-11-09 De-Cheng Zhang Composition and methods of treating allergies with reishi extract
US20080038239A1 (en) * 2006-08-14 2008-02-14 Chee-Keung Chung Method for treating and/or preventing intestinal bacterial imbalance
US20080038288A1 (en) * 2006-08-14 2008-02-14 Chee-Keung Chung Prevention of damage in hippocampus of fetus/newborn infant due to maternal gestational hypertension
CN109512931A (zh) 2012-09-13 2019-03-26 江中药业股份有限公司 改善男性性功能的组合物及其应用
US10940162B2 (en) 2016-11-08 2021-03-09 PT. Sahabat Lingkungan Hidup Use of polysaccharide for treating ST-elevation myocardial infarction and diseases of the digestion system
JP7886899B2 (ja) * 2021-05-11 2026-07-08 シャオチ シン 乾癬の治療のための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63109754A (ja) * 1986-10-27 1988-05-14 Yasahiro Morita 霊芝調味料の製造法
DE3886986T2 (de) * 1987-04-28 1994-08-11 Meiji Milk Prod Co Ltd Glykoprotein, Verfahren zu dessen Herstellung und dieses als aktiven Bestandteil enthaltendes immunsuppressives Agens.
US6316002B1 (en) * 1999-10-12 2001-11-13 Xin Liu Germination activated red Ganoderma lucidum spores and method for producing the same
CN1111068C (zh) 2000-07-27 2003-06-11 上海北医大生物科技有限公司 一种葡萄籽提取物opc强抗氧化复合胶囊及其制造方法

Also Published As

Publication number Publication date
ES2311086T3 (es) 2009-02-01
DE60322310D1 (de) 2008-09-04
CN1480207A (zh) 2004-03-10
US6893641B2 (en) 2005-05-17
US20030143246A1 (en) 2003-07-31
JP2004099613A (ja) 2004-04-02
EP1398036A1 (de) 2004-03-17
EP1398036B1 (de) 2008-07-23
CA2437690A1 (en) 2004-03-05

Similar Documents

Publication Publication Date Title
WO1999066917A3 (en) Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid
Lu et al. Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to opiate dependence in rats
Cowley Jr et al. Cardiovascular actions of vasopressin
BR9809951A (pt) Método para tratamento da obesidade
BR9710585A (pt) Composição para administração enteral, processo para melhorar a resistência fìsica ou desempenho atlético de um mamìfero, para aumentar a concentração de proteìna, massa corporal sem gordura ou massa muscular em um mamìfero, para diminuir a deposição de gordura corporal para uma dada ingestão calórica e aumentar a perda de gordura corporal em um mamìfero, para tratar os efeitos catabólicos de doença em um mamìfero, para aperfeiçoar a resistência fìsica ou o desempenho atléticode um mamìfero, e, para aumentar a massa de um corpo de carne magra de um mamìfero e diminuir a deposição de gordura
WO2002015920A3 (en) Treatment of hyperproliferative diseases
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
DE60322310D1 (de) Ganoderma lucidum Sporen zur Behandlung von systemischem lupus erytrhomatosus (SLE)
WO2006057003A3 (en) Induction of neurogenesis and stem cell therapy in combination with copolymer 1
TW200719908A (en) Dermatologic use of milk proteins
Wako et al. Glial uptake of intracerebroventricularly injected D-serine in the rat brain: an immunocytochemical study
Shan et al. Area postrema ablation attenuates activation of neurones in the paraventricular nucleus in response to systemic adrenomedullin
EP0921820A4 (de) Genterapie für die fettleibigkeit
NO20055187L (no) Fremgangsmate for behandling og forebygging av lavere urinkanal symptomer
ATE338819T1 (de) Antigenes protein aus malassezia
Weiner Effect of centrally active drugs on the action of coumarin anticoagulants
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
RU96114157A (ru) Способ лечения острых отравлений
EP0642333A4 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion.
KR890015746A (ko) 메게스트롤 아세테이트로 aids 악액질을 치료하는 방법
RU1806743C (ru) Способ лечени алкоголизма
Martiny et al. Autocrine biological effects of glycosyl inositol phosphate produced by reconstituted pig thyroid follicles: role of pertussis toxin sensitive G proteins
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
RU2111762C1 (ru) Вещество, способное снижать влечение к этанолу
RU2002108764A (ru) Способ лечения заболеваний желудочно-кишечного тракта телят

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties